Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Global First: Assessment of Sleep Apnoea and Select Sleep Disorders in an African Cohort
Cerebrovascular Disease and Interventional Neurology
P14 - Poster Session 14 (8:00 AM-9:00 AM)
4-009

To characterise the prevalence of obstructive sleep apnoea (OSA) and select sleep disorders in a Nigerian cohort, and their association with ischaemic stroke (IS).  To our knowledge, this is the first study of its kind.


OSA is associated with cerebro- and neurovascular disorders such as IS and myocardial infarction (MI), respectively.  Untreated OSA is a risk factor for IS, and the risk of OSA after IS also increases.  Yet the relationship between OSA and IS are poorly studied in African populations.  In fact, there is no available published study on the risk of OSA on cerebrovascular disease in African populations.  Most studies on this topic have been in Western populations, yet a plethora of studies demonstrate that findings from research in caucasians may not be generalisable to non-caucasian populations.  Genetic, epigenetic and environmental differences are also important in disease manifestation.  For these and other reasons, populations of African origin must be adequately represented in research if the findings are to have general applicability.

Cross-sectional and prospective study of a cohort in Ibadan, Nigeria aged 55 and older.  Widespread polysomnography is not feasible for financial and infrastructural reasons, so our protocol is centred on an extensive toolkit of surrogate indicators that screen for OSA, including STOP-BANG score and Epworth Sleepiness Scale.  The end-point is diagnosis of MI, transient ischaemic attack or IS at any time after screening, with initial follow up from 1 to 6 months, then annually after that.

Initial feasibility studies, pilot data collection and preliminary analysis are anticipated by April 2020.

Our study is the first to investigate the prevalence of OSA and the important connection between OSA, cardiovascular and cerebrovascular diseases on the African continent.  It has significant implications for the development of research projects in resource-limited settings within the global context.
Authors/Disclosures
N. Abimbola Sunmonu, MD, PhD (Yale Neurology)
PRESENTER 		Dr. Sunmonu has nothing to disclose.
Rufus O. Akinyemi, MD (Institute for Advanced Medical Research and Training) Dr. Akinyemi has nothing to disclose.
Mayowa Owolabi, MD, FÂ鶹´«Ã½Ó³»­ (Neurology Unit, Dept of Med, UCH) Dr. Owolabi has nothing to disclose.
Nina J. Solenski, MD (UVA - Neurology) Dr. Solenski has received personal compensation in the range of $0-$499 for serving as an Expert Witness for Multiple. The institution of Dr. Solenski has received research support from HRSA . Dr. Solenski has received intellectual property interests from a discovery or technology relating to health care.
Bradford B. Worrall, MD, MSc, FÂ鶹´«Ã½Ó³»­ (University Of Virginia Health System) The institution of Dr. Worrall has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Â鶹´«Ã½Ó³»­. The institution of Dr. Worrall has received research support from NIH. The institution of Dr. Worrall has received research support from AHA/ASA.